S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Asian benchmarks trade mixed amid expectations for US rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Asian benchmarks trade mixed amid expectations for US rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Asian benchmarks trade mixed amid expectations for US rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Asian benchmarks trade mixed amid expectations for US rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
LON:ROQ

Roquefort Therapeutics (ROQ) Share Price, News & Analysis

GBX 4.55
0.00 (0.00%)
(As of 04/16/2024 ET)
Today's Range
4.53
4.60
50-Day Range
4
9.25
52-Week Range
3.90
9.50
Volume
429,545 shs
Average Volume
322,713 shs
Market Capitalization
£5.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ROQ stock logo

About Roquefort Therapeutics Stock (LON:ROQ)

Roquefort Therapeutics plc, a biotechnology company, engages in the development of medicines for the treatment of cancer. The company's pre-clinical development pipeline comprises Midkine antibodies with significance in vivo efficacy and toxicology studies; Midkine RNA therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics with novel anti-cancer approach; STAT-6 siRNA therapeutics targeting solid tumors with significance in vivo efficacy; and MK cell therapy with direct and NK-mediated anti-cancer action. Roquefort Therapeutics plc was incorporated in 2020 and is based in London, the United Kingdom.

ROQ Stock Price History

ROQ Stock News Headlines

Can't believe it's happening again
One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.
NBSE NeuBase Therapeutics, Inc.
Can't believe it's happening again
One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.
Roquefort Therapeutics making headway with siRNA
Roquefort Therapeutics eyes second half progress
Roquefort Therapeutics has no exposure to SVB
Roquefort Therapeutics establishes scientific advisory board
Roquefort Thera Regulatory News
Roquefort Therapeutics PLC
Roquefort Therapeutics inks Randox diagnostic deal
See More Headlines
Receive ROQ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Roquefort Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
9
Year Founded
N/A

Profitability

Net Income
£-1,640,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£637.00
Cash Flow
GBX 3.04 per share
Book Value
GBX 5 per share

Miscellaneous

Free Float
N/A
Market Cap
£5.88 million
Optionable
Not Optionable
Beta
-0.03
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Stephen Paul West B.Com (Age 52)
    CA, Executive Chairman
    Comp: $118.31k
  • Mr. Trevor Ajanthan Reginald (Age 52)
    CEO & Executive Director
    Comp: $284.1k
  • Prof. Martin J. Evans FRS (Age 83)
    Group Chief Scientific Officer & Executive Director
    Comp: $101.22k
  • Dr. Emma Morris
    Head of Pre-Clinical Research

ROQ Stock Analysis - Frequently Asked Questions

How have ROQ shares performed in 2024?

Roquefort Therapeutics' stock was trading at GBX 7.25 at the start of the year. Since then, ROQ stock has decreased by 37.2% and is now trading at GBX 4.55.
View the best growth stocks for 2024 here
.

How do I buy shares of Roquefort Therapeutics?

Shares of ROQ stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:ROQ) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners